Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of pipeline of late-stage clinical and commercial products. The company is headquartered in Henderson, Nevada and currently employs 235 full-time employees. The firm operates through developing and commercializing oncology and hematology drug products segment. The company focuses on developing ROLONTIS and POZIOTINIB. ROLONTIS is being investigated for the treatment of chemotherapy-induced neutropenia. POZIOTINIB is an oral pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR, HER) Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.